Phase II neoadjuvant pyrotinib combined with epirubicin and cyclophosphamide followed by docetaxel in HER2-low–expressing and HR-positive early or locally advanced breast cancer (PILHLE-001): A single ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback